BMRN
$BMRN
BioMarin Pharmaceutical Inc.
Rare disease biotech company with gene therapy and enzyme replacement treatments.
HealthcareSubscribers
0
Tracking this ticker
Next Report
—
Weekly updates
Latest Report
This week's analysis
BMRN: Pipeline Recovery & Valuation Upside
BioMarin ($BMRN) trades at $55.83 with a strong buy consensus and a mean analyst target near $88.9. Forward P/E and PEG point to material upside if pipeline and guidance trends improve.
Apr 6, 2026